CD4 and influenza: These saRNA vaccine candidates induced both CD4+ Th1 and CD8+ T-cell responses and protected the mice against lethal challenge from both homologous (H1N1) and heterosubtypic (H3N2) influenza strains, highlighting the potential of the saRNA platform towards the development of broad-spectrum universal influenza vaccines.